Prognostic factors in HIV-related diffuse large-cell lymphoma: Before versus after highly active antiretroviral therapy

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8477-8482

  Lim, Soon Thye ^a   Karim, Roksana ^a   Tulpule, Anil ^a   Nathwani, Bharat N ^a   Levine, Alexandra M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; B CELL LYMPHOMA; COMPARATIVE STUDY; HEALTH SURVEY; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33644675524     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.9355     Document Type: Review

References (24)

1. Kaplan LD, Straus DJ, Testa MA, et al: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 336:1641-1648, 1997
2. Levine AM, Wernz JC, Kaplan L, et al: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma: A prospective multi-institutional trial. JAMA 266:84-88, 1991
3. Straus DJ, Huang J, Testa MA, et al: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group Protocol 142-Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor: National Institute of Allergy and Infectious Diseases. J Clin Oncol 16:3601-3606, 1998
4. Vaccher E, Tirelli U, Spina M, et al: Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients. J Clin Oncol 14:2217-2223, 1996
5. Rossi G, Donisi A, Casari S, et al: The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 86:2391-2397, 1999
6. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 338:853-860, 1998
7. Gerard L, Galicier L, Boulanger E, et al: Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17:81-87, 2003
8. Navarro JT, Lloveras N, Ribera JM, et al: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 90:704-706, 2005
9. Tam HK, Zhang ZF, Jacobson LP, et al: Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 98:916-922, 2002
10. Vaccher E, Spina M, Talamini R, et al: Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 37:1556-1564, 2003
11. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653-4659, 2003
12. Levine AM, Tulpule A, Espina B, et al: Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: Results of therapy and correlates of response. J Clin Oncol 22:2662-2670, 2004
13. Lim ST, Roksana K, Nathwani B, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active anti-retroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy J Clin Oncol 23:4430-4438, 2005
14. Spina M, Jaeger U, Sparano JA, et al: Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials. Blood 105:1891-1897, 2005
15. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982
16. Bower M, Gazzard B, Mandalia S, et al: A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143:265-273, 2005
17. Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. Cancer 34:1488-1503, 1974 (suppl 4)
18. Altman GD: Practical Statistics for Medical Research. London, United Kingdom, Chapman and Hall, 1991
19. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
20. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
21. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004
22. Milpied N, Deconinck E, Gaillard F, et al: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295, 2004
23. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Étude des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
24. Mounier N, Spina M, Gabarre J, et al: Treatment of human immunodeficiency virus-related lymphoma with risk-adapted intensive chemotherapy: Final analysis of the NHL-HIV 93 trial. J Clin Oncol 23:566S, 2005 (suppl, abstr 6524)